<DOC>
	<DOCNO>NCT01614756</DOCNO>
	<brief_summary>The purpose study determine safety tolerability IL-31 mAB</brief_summary>
	<brief_title>A Two-Part , Phase 1 , Single-Dose Study IL-31 mAb ( Anti-Interleukin 31 Monoclonal Antibody ) ; Healthy Subjects Adults With Atopic Dermatitis</brief_title>
	<detailed_description>Healthy Volunteers acceptable `` Part 2 '' ( Adult subject Atopic Dermatitis ) Enrollment : ( Part 1 Part 2 ) Part 2 consist 42 patient atopic dermatitis</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Part 1 : Healthy subject Part 2 : Adult subject : 1 . Atopic dermatitis severity assess Physician Global Assessment rating 3 high ( i.e. , moderate great ) scale 0 5 2 . Pruritus severity least 7 10 visual analog scale Receipt systemic immunosuppressant , biological agent , topical calcineurin inhibitor ( tacrolimus pimecrolimus ) within 4 week prior study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>